PRO/AH/EDR> COVID-19 update (261): Singapore, mental illness, vaccine mix & match, WHO

COVID-19 -- Singapore
"Background
To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK).
"Methods
We did a phase 2, open-label, randomised, controlled trial on adults aged 18-60 years, vaccinated with a single dose of ChAdOx1-S 8-12 weeks before screening,

Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?8554984&promed&0